TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes

PR57074

PARIS, Jun. 17 /PRN=KYODO JBN/ --

        Findings set foundation to drive recommendations for enhancing care

    Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the first results of

the TEENs Registry Study, the largest contemporary real-world study of the care

of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings

not only highlighted that over 70% of youths are not attaining their blood

sugar target levels (measured by HbA1C), but also that achieving target HbA1C

is associated with a significantly better quality of life (QoL) for young

people (p＜0.05).

    The TEENs Study investigated factors associated with better blood sugar

control (defined as achieving target HbA1C levels recommended by international

organizations) and QoL per age class, with three predefined age groups of 8-12,

13-18, and 19-25 years. The key factors identified were a younger age (8 to 12

years), balanced family support for diabetes management, and absence of family

financial burden related to diabetes. The TEENs Study findings will help set a

foundation for recommendations to enhance care aimed at improving disease

management and patient outcomes. The findings were presented at the 74th

Scientific Sessions of the American Diabetes Association in San Francisco.

    "The TEENs Study provides exceptional, contemporary data related to the

care and outcomes of young people with type 1 diabetes from around the globe.

In particular, the study aimed at identifying modifiable barriers to diabetes

management, especially during the transition from pediatric to adult care, and

is providing an assessment of the challenges facing teens with type 1 diabetes

and a unique view of young adults," said Lori Laffel MD MPH, Associate

Professor/Chief of the Pediatric, Adolescent and Young Adult Section of the

Joslin Diabetes Center, Harvard Medical School, Boston, U.S. and Co-Chair of

the TEENs Registry Study Steering Committee. "The findings from the TEENs Study

can help us to design new approaches to care that can overcome many of the

challenges associated with suboptimal glycemic control and psychosocial burdens

of care in order to help young people with type 1 diabetes and their families."

    "Sanofi is committed to advancing knowledge in type 1 diabetes to improve

disease management and outcomes," said Pierre Chancel, Senior Vice President,

Global Diabetes, Sanofi. "Overall, insights from TEENS give us a unique

opportunity to better assess the unmet needs of children, teens and young

adults with type 1 diabetes, thereby enhancing their glycemic control and

quality of life as well as limiting their risk of long-term complications."

    Sanofi has partnered with more than 200 clinics, centers and hospitals,

notably with the T1D Exchange in the US, for interviewing healthcare providers,

youths with type 1 diabetes, and their families in 20 countries (within Europe,

the US, Latin America, Middle East, North Africa, South Africa, India). The

results showed that achieving target HbA1C was associated with a significantly

better QoL (p＜0.05) in a real life setting. The TEENs Study findings also

showed that over 70% of people aged 8 to 25 years were not achieving their

HbA1C target according to international guidelines, with only 32% of 8 to 12

year olds and 29% of 13 to 18 year olds (ISPAD guidelines), and 19% of 19 to 25

year olds (ADA guidelines) reaching HbA1C targets.

    Furthermore, the TEENs findings suggest that young people with type 1

diabetes can increase their chances of reaching their target HbA1C levels and

having a better QoL by modifying approaches to diabetes management and

education, such as using advanced intensive insulin regimens, performing

frequent blood sugar monitoring (more than three times a day), engaging in

regular exercise, and attending to dietary management. Family support has also

been identified as a key factor influencing glycemic control (family

involvement, absence of diabetes-specific family conflicts), as well as

maintaining parental working activities, which was also linked to better QoL

for young people with type 1 diabetes. Absence of financial burden related to

diabetes was also associated with better glycemic control and QoL for young

people with type 1 diabetes.

    The TEENs abstracts are titled:

    1) Global Assessment of Factors Associated with Target Glycemic Control in

Youth with Type 1 Diabetes (T1D): the TEENs Study (Laffel et al. Oral

presentation, June 13, 6:00 pm PST, abstract # 32-OR)

    2) Opportunities to Enhance Diabetes-specific Quality of Life (QoL) in

Youth with Type 1 Diabetes (T1D): the Global TEENs Study (Anderson et al. Oral

presentation, June 16, 9:00 am PST, abstract # 259-OR)

    3) Diabetes-specific Health-related Quality of Life (QoL) in a Sample of US

Youth with Type 1 Diabetes (T1D) in the TEENs Study (Anderson et al. Poster

presentation, June 14, 11:30 am to 1:30 pm PST, abstract # 1247-P)

    About Sanofi

    Sanofi, a global healthcare leader, discovers, develops and distributes

therapeutic solutions focused on patients' needs. Sanofi has core strengths in

the field of healthcare with seven growth platforms: diabetes solutions, human

vaccines, innovative drugs, consumer healthcare, emerging markets, animal

health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in

New York (NYSE: SNY).

    Forward Looking Statements

    Sanofi Forward Looking Statements

    This press release contains forward-looking statements as defined in the

Private Securities Litigation Reform Act of 1995, as amended. Forward-looking

statements are statements that are not historical facts. These statements

include projections and estimates and their underlying assumptions, statements

regarding plans, objectives, intentions and expectations with respect to future

financial results, events, operations, services, product development and

potential, and statements regarding future performance. Forward-looking

statements are generally identified by the words "expects", "anticipates",

"believes", "intends", "estimates", "plans" and similar expressions. Although

Sanofi's management believes that the expectations reflected in such

forward-looking statements are reasonable, investors are cautioned that

forward-looking information and statements are subject to various risks and

uncertainties, many of which are difficult to predict and generally beyond the

control of Sanofi, that could cause actual results and developments to differ

materially from those expressed in, or implied or projected by, the

forward-looking information and statements. These risks and uncertainties

include among other things, the uncertainties inherent in research and

development, future clinical data and analysis, including post marketing,

decisions by regulatory authorities, such as the FDA or the EMA, regarding

whether and when to approve any drug, device or biological application that may

be filed for any such product candidates as well as their decisions regarding

labelling and other matters that could affect the availability or commercial

potential of such product candidates, the absence of guarantee that the product

candidates if approved will be commercially successful, the future approval and

commercial success of therapeutic alternatives, the Group's ability to benefit

from external growth opportunities, trends in exchange rates and prevailing

interest rates, the impact of cost containment policies and subsequent changes

thereto, the average number of shares outstanding as well as those discussed or

identified in the public filings with the SEC and the AMF made by Sanofi,

including those listed under "Risk Factors" and "Cautionary Statement Regarding

Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year

ended December 31, 2013. Other than as required by applicable law, Sanofi does

not undertake any obligation to update or revise any forward-looking

information or statements.

    SOURCE: Sanofi Diabetes